Statins in COPD Selection Modalities and Mortalities
To the Editor:
Cardiovascular disease contributes a significant share to the all-cause mortality of COPD 1 ; therefore it is sensible to assume similar positive outcomes with its mortality benefiting measures in the COPD group as well. The study by Raymakers 
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We thank Sakhamuri and Chattu for their comments on our study. 1 The main criticisms raised in their letter were the following: (1) the age restriction for the cohort of patients with COPD clashes with the literature we cited; (2) the cohort was restricted to those without previous cardiovascular disease (CVD); and (3) the case definition for COPD was based on filled prescriptions for COPDrelated, albeit not COPD-specific, medications. We appreciate these concerns and contend that they are largely limitations of administrative data and that we have appropriately identified and responded to these criticisms in our article (see the Discussion section); we do, however, address each point specifically here.
First, there were concerns that in the beginning of our paper we referred to a population of patients with COPD who were > 30 years of age whereas our study used an age criterion of 50 years of age or older. The View publication stats View publication stats
